\-\ Texto\\:\\ \ \(0\)\
\-\ leukocytosis\\.\ \(11\)\
\-\ \\â\\€\\¢\\ cxr\\:\\ \\ interstitial\\ pattern\\,\\ pulmonary\\ nodules\\,\\ and\\ faint\\ mass\\ on\\ the\\ right\\.\\ \\ \ \(0\)\
\-\ \\â\\€\\¢\\ ct\\:\\ \\ multiple\\ cavitary\\ and\\ noncavitary\\ nodules\\ and\\ masses\\.\ \(0\)\
\-\ caplan\\ syndrome\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ vasculitis\ \(1\)\
\-\ \\â\\€\\¢\\ septic\\ emboli\ \(0\)\
\-\ \\â\\€\\¢\\ infection\ \(8\)\
\-\ 55\\ y\\.o\\.\\ coal\\ miner\\ approximately\\ two\\ months\\ status\\ post\\ posterior\\ cervical\\ fusion\\ for\\ c2\\-c3\\ instability\\.\\ \\ routine\\ clinical\\ followup\\ shows\\ a\\ leukocytosis\\.\\ \\ the\\ patient\\ has\\ known\\ rheumatoid\\ arthritis\\ and\\ exposure\\ to\\ coal\\ dust\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ coal\\:\\ 0\\.43751785974007384\ \(0\)\
\-\ leukocytosis\\:\\ 0\\.3127978600492933\ \(0\)\
\-\ noncavitary\\:\\ 0\\.2289342835723957\ \(0\)\
\-\ nodules\\:\\ 0\\.2274889465186921\ \(0\)\
\-\ caplan\\:\\ 0\\.2115394015247185\ \(0\)\
\-\ miner\\:\\ 0\\.2115394015247185\ \(0\)\
\-\ dust\\:\\ 0\\.20593950028631944\ \(0\)\
\-\ faint\\:\\ 0\\.16015150515985577\ \(0\)\
\-\ cavitary\\:\\ 0\\.15710589255116147\ \(0\)\
\-\ emboli\\:\\ 0\\.14043846752690547\ \(0\)\
\-\ septic\\:\\ 0\\.13604822261992905\ \(0\)\
\-\ exposure\\:\\ 0\\.13604822261992905\ \(0\)\
\-\ instability\\:\\ 0\\.1348385662885064\ \(0\)\
\-\ vasculitis\\:\\ 0\\.132852574863747\ \(0\)\
\-\ interstitial\\:\\ 0\\.12977580705543731\ \(0\)\
\-\ followup\\:\\ 0\\.12639462388710188\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.12618461839325196\ \(0\)\
\-\ 55\\:\\ 0\\.12304358547922832\ \(0\)\
\-\ fusion\\:\\ 0\\.1202523214336076\ \(0\)\
\-\ and\\:\\ 0\\.1183240201739329\ \(0\)\
\-\ arthritis\\:\\ 0\\.11643104789779973\ \(0\)\
\-\ cxr\\:\\ 0\\.11452068493172235\ \(0\)\
\-\ routine\\:\\ 0\\.11085951920065577\ \(0\)\
\-\ pattern\\:\\ 0\\.10687773105692448\ \(0\)\
\-\ cervical\\:\\ 0\\.10252938883135987\ \(0\)\
\-\ status\\:\\ 0\\.09990161402889004\ \(0\)\
\-\ masses\\:\\ 0\\.09745644679836735\ \(0\)\
\-\ known\\:\\ 0\\.09268208568357165\ \(0\)\
\-\ approximately\\:\\ 0\\.09134262637047838\ \(0\)\
\-\ clinical\\:\\ 0\\.09072422522215835\ \(0\)\
\-\ pulmonary\\:\\ 0\\.0872589141196935\ \(0\)\
\-\ infection\\:\\ 0\\.08647325137950809\ \(0\)\
\-\ syndrome\\:\\ 0\\.08630195030436666\ \(0\)\
\-\ two\\:\\ 0\\.08501258503747311\ \(0\)\
\-\ shows\\:\\ 0\\.08401896712858901\ \(0\)\
\-\ months\\:\\ 0\\.08332716347300746\ \(0\)\
\-\ metastatic\\:\\ 0\\.07851276423202033\ \(0\)\
\-\ post\\:\\ 0\\.07789461696863309\ \(0\)\
\-\ posterior\\:\\ 0\\.07402612703118826\ \(0\)\
\-\ multiple\\:\\ 0\\.07001969811874068\ \(0\)\
\-\ has\\:\\ 0\\.06538853972720828\ \(0\)\
\-\ disease\\:\\ 0\\.0600909302419732\ \(0\)\
\-\ the\\:\\ 0\\.05712878854785392\ \(0\)\
\-\ mass\\:\\ 0\\.05468097610301049\ \(0\)\
\-\ ct\\:\\ 0\\.05450004157686797\ \(0\)\
\-\ right\\:\\ 0\\.04746144775769211\ \(0\)\
\-\ patient\\:\\ 0\\.046560783847932975\ \(0\)\
\-\ for\\:\\ 0\\.043388854641835624\ \(0\)\
\-\ on\\:\\ 0\\.04323494118749058\ \(0\)\
\-\ to\\:\\ 0\\.03578819892667105\ \(0\)\
